LEGENDS TO SUPPLEMENTARY FIGURES

Supplementary Figure 1: Inter-relationships between somatic mutations in the EGFR pathway and MSI-status in aCRC. KRAS and BRAF mutations were, in general, mutually exclusive. Mutations in PIK3CA were more frequently observed in those CRCs with KRAS mutations than in those without \( (P=3.1\times10^{-4}) \) and MSI was associated with BRAF mutations \( (P=5.3\times10^{-10}) \). CRCs with BRAF mutations are shaded in light grey and those with MSI are shaded in dark grey.

Supplementary Figure 2: Kaplan-Meier plots of OS (A,B) and PFS (C,D) for patients with PIK3CA wild type (A,C) or mutant (B,D) tumours. Neither sets of patients showed improved OS or PFS after treatment with cetuximab.

Supplementary Figure 3: Kaplan-Meier plots of OS (A,B) and PFS (C,D) for patients with PIK3CA wild type (A,C) or mutant (B,D) tumours, that were also KRAS wild type. Neither sets of patients showed improved OS or PFS after treatment with cetuximab.